Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23234760 | 0.86 | LPL (0.40) | LPLLIPGJAK2BTKDGAT1 | |
| SCHEMBL26623591 | 0.82 | LPL (0.37) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL29424567 | 0.81 | LPL (0.50) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL21042445 | 0.81 | LIPG (0.50) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL897058 | 0.81 | LPL (0.50) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL37395635 | 0.80 | LPL (0.41) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL6120636 | 0.80 | LPL (0.41) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL12476110 | 0.80 | LPL (0.34) | LPLLIPGPYCR1P2RX7 | |
| SCHEMBL17491867 | 0.80 | LPL (0.53) | LPLLIPGEGFRROCK1 | |
| SCHEMBL2355702 | 0.79 | LPL (0.40) | LPLLIPGJAK2BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258365-B2 | Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof | BETA PHARMA, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3893872-B1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3893872-B1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-116253755-A | Synthesis method of diaryl borate compound | 湖南大学 | 2023-06-13 | — | — | CN | disclosed |
| EP-3893872-A1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | Beta Pharma, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020124060-A1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020124060-A1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258365-B2 | Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof | MET, ALK, TYRO3 | LPL 2304/4885LIPG 984/4885JAK2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.